PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
3.65%
D&A growth of 3.65% while Healthcare median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
SBC declines yoy while Healthcare median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-515.11%
Working capital is shrinking yoy while Healthcare median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Growth of 21.40% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-12704.62%
Other non-cash items dropping yoy while Healthcare median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-57.07%
Negative CFO growth while Healthcare median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-196.22%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance growth of 100.00% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.